CL2024000782A1 - Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimer - Google Patents

Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimer

Info

Publication number
CL2024000782A1
CL2024000782A1 CL2024000782A CL2024000782A CL2024000782A1 CL 2024000782 A1 CL2024000782 A1 CL 2024000782A1 CL 2024000782 A CL2024000782 A CL 2024000782A CL 2024000782 A CL2024000782 A CL 2024000782A CL 2024000782 A1 CL2024000782 A1 CL 2024000782A1
Authority
CL
Chile
Prior art keywords
compositions
compounds
thc
tocopherol
melatonin
Prior art date
Application number
CL2024000782A
Other languages
English (en)
Spanish (es)
Inventor
S Rao Jagadeesh
Ramachandra Makunda
Original Assignee
Igc Pharma Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igc Pharma Ip Llc filed Critical Igc Pharma Ip Llc
Publication of CL2024000782A1 publication Critical patent/CL2024000782A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2024000782A 2021-09-17 2024-03-15 Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimer CL2024000782A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163245799P 2021-09-17 2021-09-17

Publications (1)

Publication Number Publication Date
CL2024000782A1 true CL2024000782A1 (es) 2024-09-23

Family

ID=83688895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000782A CL2024000782A1 (es) 2021-09-17 2024-03-15 Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimer

Country Status (8)

Country Link
US (1) US20250275935A1 (enExample)
EP (1) EP4401717A1 (enExample)
JP (1) JP2024535871A (enExample)
CA (1) CA3232209A1 (enExample)
CL (1) CL2024000782A1 (enExample)
CO (1) CO2024004628A2 (enExample)
PE (1) PE20241236A1 (enExample)
WO (1) WO2023044433A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
CN121040357A (zh) * 2024-06-04 2025-12-02 河北农业大学 一种增加黄水仙生物碱加兰他敏的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR44305E (fr) 1933-12-09 1934-12-24 Meaf Mach En Apparaten Fab Nv Circuits de voie à rails sans potentiel ou portés au même potentiel
US11065225B1 (en) 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
US10525093B2 (en) * 2016-11-14 2020-01-07 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US20200246404A1 (en) * 2017-02-15 2020-08-06 Molecular Infusions, Llc Formulations
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
EP4025199A4 (en) * 2019-07-12 2023-08-02 University of South Florida Compositions and methods for treating alzheimers disease

Also Published As

Publication number Publication date
CO2024004628A2 (es) 2024-05-10
CA3232209A1 (en) 2023-03-23
EP4401717A1 (en) 2024-07-24
JP2024535871A (ja) 2024-10-02
PE20241236A1 (es) 2024-06-19
US20250275935A1 (en) 2025-09-04
WO2023044433A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Wang et al. Silibinin prevents autophagic cell death upon oxidative stress in cortical neurons and cerebral ischemia-reperfusion injury
CO2024004628A2 (es) Composiciones y métodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinación de thc y melatonina
US12465589B2 (en) Method and composition for treating CNS disorders
Choi et al. Baicalein protects HT22 murine hippocampal neuronal cells against endoplasmic reticulum stress-induced apoptosis through inhibition of reactive oxygen species production and CHOP induction
Attia et al. Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood
Wang et al. Inhibition of beta-amyloid-induced neurotoxicity by pinocembrin through Nrf2/HO-1 pathway in SH-SY5Y cells
Guo et al. Tangeretin alters neuronal apoptosis and ameliorates the severity of seizures in experimental epilepsy-induced rats by modulating apoptotic protein expressions, regulating matrix metalloproteinases, and activating the PI3K/Akt cell survival pathway
EP4640275A3 (en) USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME ANXIETY
MX2023013338A (es) Derivados de cannabidiol-c4 para el tratamiento de epilepsia.
Jiang et al. Inhibition of the integrated stress response reverses oxidative stress damage-induced postoperative cognitive dysfunction
CA2956919C (en) Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids
Huang et al. Garlic essential oil mediates acute and chronic mild stress-induced depression in rats via modulation of monoaminergic neurotransmission and brain-derived neurotrophic factor levels
Tao et al. Advances in autophagy modulation of natural products in cervical cancer
BR112022021640A2 (pt) Usos e formulações de canabinoides
Bian et al. Apigenin-7-diglucuronide protects retinas against bright light-induced photoreceptor degeneration through the inhibition of retinal oxidative stress and inflammation
Petraglia et al. Stuck at the bench: Potential natural neuroprotective compounds for concussion
Joseph et al. Effects of aerobic exercise and dietary flavonoids on cognition: a systematic review and meta-analysis
Nadeem et al. Exploring the neuroprotective role of Asparagus racemosus (Shatavari) in Alzheimer’s disease: mechanisms, evidence, and future directions
MX2022016038A (es) Uso de cannabidiol en el tratamiento de la epilepsia.
Dutta A study from structural insight to the antiamyloidogenic and antioxidant activities of flavonoids: Scaffold for future therapeutics of Alzheimer’s disease
Fan et al. LED enhances anti-inflammatory effect of luteolin (3’, 4’, 5, 7-tetrahydroxyflavone) in vitro
US6569471B2 (en) Method for the treatment of symptoms related to normal hormonal variations in women
Kamila et al. The Role of Lavender Essential Oils (LEO) in Managing Stress and Neuroinflammation: An Immunopsychiatric Perspective
Negi et al. Neurovascular Coupling Dysfunction: Natural Products as a Remedy to Manage Neurodegenerative Disorders
Singh et al. Recent progress in the pharmacology of phytoestrogens: emerging neuromodulators for treating anxiety and depression